Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)

COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES (2022) Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou J, Hu PH, et al. Conference contribution Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States (2022) Fasching P, Huang M, Haiderali A, Xue W, Pan W, Zhou ZY, Hu P, et al. Conference contribution Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1 (2022) Fasching P, Huang M, Haiderali A, Pan W, Hu P, Chaudhuri M, De Tilleghem CLB, et al. Conference contribution Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, et al. Journal article Non-invasive imaging as the cornerstone of cardiovascular precision medicine (2022) Achenbach S, Fuchs F, Goncalves A, Kaiser-Albers C, Ali ZA, Bengel FM, Dimmeler S, et al. Journal article Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (2022) Huang M, Haiderali A, Fox GE, Frederickson A, Cortes J, Fasching P, O'Shaughnessy J Journal article, Review article Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies (2022) Gorski M, Rasheed H, Teumer A, Thomas LF, Graham SE, Sveinbjornsson G, Winkler TW, et al. Journal article KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC (2021) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kummel S, Bergh J, et al. Conference contribution Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article